Efficacy and safety of standard BEACOPP regimen versus ABVD regimen for treatment of advanced Hodgkin's lymphoma.
Humans
Hodgkin Disease
/ drug therapy
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Bleomycin
/ administration & dosage
Doxorubicin
/ administration & dosage
Vincristine
/ adverse effects
Male
Procarbazine
/ administration & dosage
Adult
Cyclophosphamide
/ administration & dosage
Female
Etoposide
/ administration & dosage
Prednisone
/ administration & dosage
Dacarbazine
/ adverse effects
Middle Aged
Young Adult
Vinblastine
/ administration & dosage
Adolescent
Neoplasm Staging
Treatment Outcome
Journal
Journal of cancer research and therapeutics
ISSN: 1998-4138
Titre abrégé: J Cancer Res Ther
Pays: India
ID NLM: 101249598
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
06
03
2023
accepted:
03
06
2024
medline:
1
9
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
ppublish
Résumé
The current treatment regimens for Hodgkin's lymphoma (HL) are associated with high incidences of adverse events. This study aimed to compare the efficacy and safety of doxorubicin + bleomycin + vincristine + dacarbazine (ABVD) and standard bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisone (BEACOPP) chemotherapy in the treatment of advanced stage HL. This multicenter, randomized, parallel, open, positive control noninferiority trial was conducted from 2016 to 2019 and comprised 93 subjects who were randomized in a 1:1 ratio between the treatment (BEACOPP; n = 44) and control (ABVD; n = 49) groups. The primary efficacy endpoint of this trial was the objective response rate (ORR) after eight cycles of chemotherapy, which was 100.00% (36/36) in the treatment group and 95.74% (45/49) in the control group. The incidence of adverse reactions was 100% in both groups. Significant differences (P < 0.05) in the incidences of grade 3 (39/44 [88.64%] vs. 23/49 [46.94%]) and grade 4 (27/44 [61.36%] vs. 8/49 [16.94%]) adverse events were observed between the treatment and control groups, respectively. However, most of these reactions were manageable, with no serious consequences, and were reversible after discontinuation of the treatment. Both regimens had a similar ORR and were associated with a high number of adverse events. The ABVD regimen was better tolerated and safer than the standard BEACOPP regimen. This study indicates that the standard BEACOPP regimen may be considered as a treatment option for patients with advanced HL.
Identifiants
pubmed: 39206988
doi: 10.4103/jcrt.jcrt_511_23
pii: 01363817-202420040-00018
doi:
Substances chimiques
Bleomycin
11056-06-7
Doxorubicin
80168379AG
Vincristine
5J49Q6B70F
Procarbazine
35S93Y190K
Cyclophosphamide
8N3DW7272P
Etoposide
6PLQ3CP4P3
Prednisone
VB0R961HZT
Dacarbazine
7GR28W0FJI
Vinblastine
5V9KLZ54CY
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1258-1264Informations de copyright
Copyright © 2024 Copyright: © 2024 Journal of Cancer Research and Therapeutics.
Références
World Health Organization. International Agency for Research on Cancer 2012. Globocan 2012 Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx Last accessed on 2017 Aug 10.
Hokland P, Shah M, David K, Evens A, Auer R, Ledieu R, et al. How I treat advanced Hodgkin lymphoma-A global view. Br J Haematol 2020;190:837–50.
Diehl V, Fuchs M. Early, intermediate and advanced Hodgkin's lymphoma:modern treatment strategies. Ann Oncol 2007;18 Suppl 9:ix71–9.
Longley J, Johnson PWM. Current treatment paradigms for advanced stage Hodgkin lymphoma. Br J Haematol 2019;184:60–71.
Diehl V, Klimm B, Re D. Hodgkin lymphoma:A curable disease:What comes next?. Eur J Haematol Suppl 2005:6–13.
Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–84.
Gisselbrecht C. Can we improve ABVD in Hodgkin's lymphoma?. Lancet Oncol 2013;14:1254–6.
Hohaus S, Di Febo A, Storti S, Teofili L, Voso MT, Leone G. Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma. Haematologica 2004;89:751–2.
Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma:An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013;31:684–91.
Zhang T, Yao Y, Feng F, Zhao W, Tian J, Zhou C, et al. Comparative effectiveness of different chemotherapy regimens of advanced-stage Hodgkin lymphoma in adults:A network meta-analysis. Cancer Manag Res 2018;10:6017–28.
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial):A randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:1791–9.
Diehl V, Behringer K. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?. Cancer Invest 2006;24 7:713–717.
Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386–95.
Lim SH, Johnson PWM. Optimizing therapy in advanced-stage Hodgkin lymphoma. Blood 2018;131:1679–88.
Jiang Y, Chen Y, Huang R, Chen G. Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment:A meta-analysis. Int J Hematol 2016;104:413–9.
André M, Bosly A. BEACOPP escalated versus ABVD in advanced Hodgkin's lymphoma. Lancet Oncol 2013;14:911–2.
Vassilakopoulos TP, Johnson PWM. HD2000 update in Hodgkin lymphoma-ABVD or BEACOPP?. J Clin Oncol 2016;34:3584–5.
Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203–12.
Dalal M, Gupta J, Price K, Zomas A, Miao H, Ashaye A. Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma:A systematic literature review. Expert Rev Hematol 2020;13:907–22.
Mondello P, Musolino C, Dogliotti I, Bohn JP, Cavallo F, Ferrero S, et al. ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma:Results from a multicenter European study. Am J Hematol 2020;95:1030–7.
Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles≥4 baseline):Final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 2014;25:1622–8.
Crump M. Time to change direction in the treatment of relapsed hodgkin lymphoma?. J Clin Oncol 2021;39:97–9.
Engert A. ABVD or BEACOPP for advanced Hodgkin lymphoma. J Clin Oncol 2016;34:1167–9.
Zhang T, Yao Y, Feng F, Zhao W, Tian J, Zhou C, et al. Comparative effectiveness of different chemotherapy regimens of advanced-stage Hodgkin lymphoma in adults:A network meta-analysis. Cancer Manag Res 2018;10:6017–28.